Aptorum Group to Undergo Reverse Merger with DiamiR Biosciences, Resulting in Significant Dilution and Proposed Reverse Stock Split

summarizeSummary

Aptorum Group is proceeding with a reverse merger with DiamiR Biosciences, a transaction critical for Aptorum's continued operations given its auditor's 'going concern' warning. The merger terms are highly dilutive for existing Aptorum shareholders, who will own approximately 30% of the combined entity, while DiamiR stockholders will own 70%. The combined company will be renamed 'Niki BioSolutions, Inc.' and trade under the ticker 'NIKI'. A reverse stock split, with a ratio between 1-for-2 and 1-for-10, is also proposed to maintain Nasdaq listing, often a sign of financial distress. Both Aptorum and DiamiR have received 'going concern' warnings, underscoring the precarious financial position of the entities involved. The approval of these proposals is effectively guaranteed by Aptorum's CEO, Ian Huen, who controls 86.71% of the voting power, diminishing the influence of other shareholders.

check_boxKey Events

• Reverse Merger Agreement

  Aptorum Group will acquire DiamiR Biosciences, with DiamiR stockholders receiving approximately 70% ownership of the combined company, and existing Aptorum shareholders retaining 30%.

• Proposed Reverse Stock Split

  Shareholders will vote on a reverse stock split at a ratio between 1-for-2 and 1-for-10, intended to boost the share price and maintain Nasdaq listing.

• Financial Distress and Going Concern

  Both Aptorum Group and DiamiR Biosciences have received 'going concern' warnings from their auditors, indicating significant financial challenges and the merger as a survival strategy.

• Leadership and Name Change

  The combined entity will be renamed 'Niki BioSolutions, Inc.' and trade under the ticker 'NIKI'. Ian Huen (current Aptorum CEO) will serve as CEO, with DiamiR's CEO and CFO taking key executive roles.

auto_awesomeAnalysis

Aptorum Group is proceeding with a reverse merger with DiamiR Biosciences, a transaction critical for Aptorum's continued operations given its auditor's 'going concern' warning. The merger terms are highly dilutive for existing Aptorum shareholders, who will own approximately 30% of the combined entity, while DiamiR stockholders will own 70%. The combined company will be renamed 'Niki BioSolutions, Inc.' and trade under the ticker 'NIKI'. A reverse stock split, with a ratio between 1-for-2 and 1-for-10, is also proposed to maintain Nasdaq listing, often a sign of financial distress. Both Aptorum and DiamiR have received 'going concern' warnings, underscoring the precarious financial position of the entities involved. The approval of these proposals is effectively guaranteed by Aptorum's CEO, Ian Huen, who controls 86.71% of the voting power, diminishing the influence of other shareholders.